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a b s t r a c t
Probiotics and prebiotics have been demonstrated to positively modulate the intestinal microflora and
could promote host health. Although some studies have been performed on combinations of probiotics
and prebiotics, constituting synbiotics, results on the synergistic effects tend to be discordant in the
published works. The first aim of our study was to screen some lactic acid bacteria on the basis of
probiotic characteristics (resistance to intestinal conditions, inhibition of pathogenic strains). Bifido-
bacterium was the most resistant genus whereas Lactobacillus farciminis was strongly inhibited. The
inhibitory effect on pathogen growth was strain dependent but lactobacilli were the most effective,
especially L. farciminis. The second aim of the work was to select glucooligosaccharides for their ability to
support the growth of the probiotics tested. We demonstrated the selective fermentability of oligo-
dextran and oligoalternan by probiotic bacteria, especially the bifidobacteria, for shorter degrees of
polymerisation and absence of metabolism by pathogenic bacteria. Thus, the observed characteristics
confer potential prebiotic properties on these glucooligosaccharides, to be further confirmed in vivo, and
suggest some possible applications in synbiotic combinations with the selected probiotics. Furthermore,
the distinctive patterns of the different genera suggest a combination of lactobacilli and bifidobacteria
with complementary probiotic effects in addition to the prebiotic ones. These associations should be
further evaluated for their synbiotic effects through in vitro and in vivo models.
1. Introduction
The gut microbiota is made up of diverse and complex microbial
communities including bacteria, fungi and protozoa. This micro-
biota plays a key role in the host’s overall health [1] through its
metabolic activities and physiological regulation such as promotion
of nutrient absorption, synthesis of bioactive compounds,
improvement of intestinal barrier function, motility, resistance to
pathogens or modulation of the immune system. Alteration of the
microbiota may cause some direct or indirect digestive pathologies
like infectious diseases and chronic inflammation [2,3], metabolic
disorders [4] or atopic diseases [5]. This has led to the development
of strategies aiming to restore or to maintain the intestinal
ecosystem through probiotics and prebiotics. Probiotics were
defined by the FAO/WHO in 2001 as “live microorganisms which,
when administered in adequate amounts, confer a health benefit
on the host” [6]. Prebiotics were defined as non-digestible food
ingredients that beneficially affect the host by selectively stimu-
lating the growth and/or the activity of one or a limited number of
bacteria in the colon, and thus improve host health [7,8]. Most of
the probiotic strains belong to the Lactobacillus and Bifidobacterium
genera, which are health promoting bacteria forming part of the
balanced intestinal microbiota [9]. The main prebiotics used are
fibres and carbohydrates, such as resistant starch, wheat bran,
inulin or oligosaccharide, which are short polymers of glycosidic
residues such as fructose in fructooligosaccharides or galactose in
galactooligosaccharides and have been demonstrated to selectively
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increase bifidobacteria and lactobacilli among the colic microflora
[10]. Glucooligosaccharides, with glucose residues linked by
specific glycosidic bonds are more recently described oligosaccha-
rides but have shown some prebiotic properties concerning phys-
iological effects on glucose metabolism or vaginal microflora
[11,12]. A novel approach combines probiotics and prebiotics in
an association defined as synbiotic [13,14] in an attempt to obtain
synergistic effects of the two compounds by an improvement of the
probiotic colonisation or metabolic effect. More recently, synbiotics
have been shown to be more effective than probiotics or prebiotics
alone in improving the quality of life in patients suffering from
ulcerative colitis [15], in colorectal cancer prevention [16] or in very
general positive regulation of the microbiota [17].
Therefore, in the present study, we aimed to i) investigate in
vitro probiotic properties for some bacterial strains: their resistance
to artificial gastric and intestinal juices and their ability to inhibit
intestinal pathogenic strains and ii) select some potential prebiotic
glucooligosaccharides, synthesised in biofermenters by maltose
acceptor reaction providing short polymers, which can support the
growth of some probiotic strains, and to demonstrate their speci-
ficity through their resistance to metabolisation by intestinal
pathogenic strains in an attempt to select some pertinent synbiotics
for potential further use in intestinal applications. Thus, we aimed
to propose some synbiotics on the basis of in vitro probiotic and
prebiotic properties.
2. Materials and methods
2.1. Strains and culture conditions
All the strains tested are listed in Table 1. Lactobacillus farciminis
CIP 103136 was obtained from Institut Pasteur Collection (Paris,
France). Bifidobacterium bifidum 02, 20 and Bifidobacterium pseudo-
catenulatum 14 were previously described new-born faeces clinical
isolates [18]. Other probiotic strains were obtained from the Lalle-
mand Company collection. The strains were stored at "80 #C in
Eugon broth (AES, Rennes, France) with 20% (v/v) glycerol (Fluka,
Butch, Switzerland) and reactivated at 37 #C under anaerobic
conditions (Anoxomat SystemWS80;MartMicrobiology, Drachten,
the Netherlands) on agar plates as indicated: (a) on Reinforcement
Clostridial Medium for the bifidobacteria (Oxoid, Cambridge, UK),
(b) on MRS (AES, Rennes, France) for the lactobacilli, Lactococcus
lactis R1058 and Pediococcus acidilactici R1001 and (c) on M17 (AES,
Rennes, France) for Streptococcus thermophilus R0083. Before the
experiments, overnight cultures were prepared in MRS broth (AES,
Rennes, France) at 37 #C under anaerobic conditions.
Potential or opportunistic pathogenic strains were obtained
from Institut Pasteur Collection (Paris, France). The strains were
stored at"80 #C in Eugon broth (AES, Rennes, France)with 20% (v/v)
glycerol (Fluka, Butch, Switzerland) and reactivated at 37 #C on agar
plates as indicated: (i) on trypcase soy (Biomérieux, Marcy l’Etoile,
France) under aerobic conditions for Escherichia coli serotype
O157:H7 CIP 103571, Salmonella enterica subsp. enterica serotype
tiphymuriumCIP 60.62Tand Enterococcus faecalisCIP 106996, (ii) on
Columbia with 5% (v/v) sheep blood (Biomérieux, Marcy l’Etoile,
France) under aerobic conditions for Listeria monocytogenes CIP
82.110T or (iii) under anaerobic conditions for Clostridium difficile
CIP 104282 and (iv) under microaerophilic conditions (GENbox
Microaer; Biomérieux, Marcy l’Etoile, France) for Campylobacter
jejuni CIP 70.2T, (v) on Sabouraud (Biomérieux, Marcy l’Etoile,
France) under aerobic conditions for Candida albicans UMIP 884.65.
2.2. Glucooligosaccharides
The glucooligosaccharides tested and synthesised by CRITT-Bio
Industries (Toulouse, France) were: oligoalternan (OA), which
consists of alternate a-(1,3)/a-(1,6)-linked glucosyl residues (DP 3
to DP 6) and is synthesised by maltose acceptor reaction catalysed
by Leuconostoc mesenteroides NRRL B-1355 alternansucrase [19],
oligodextran (OD), which consists of a-(1,6)-linked glucosyl resi-
dues (DP3 to DP 9) and is synthesised by maltose acceptor reaction
catalysed by L. mesenteroides NRRL B-512F dextransucrase [20],
resistant oligodextran (rOD), which consists of a-(1,6)-linked glu-
cosyl residues (DP3 to DP 9) with a a-(1,2)-linked glucosyl residue
located at the non-reducing end or constituting a branching point
of each oligodextran and is synthesised by maltose acceptor reac-
tion catalysed by L. mesenteroides NRRL B-1299 dextransucrase[21].
2.3. Investigation for probiotic properties
2.3.1. Resistance to simulated gastric and intestinal fluids
The simulated gastric and intestinal fluids used have been
described previously [22]. Simulated gastric juice (NaCl 125 mM,
KCl, 7 mM, NaHCO3, 45 mM, pepsin, 3 g/L) at a final pH adjusted to
2.5 was inoculatedwith probiotic strain overnight cultures at a final
concentration of 1 $ 107 CFU/mL. Suspensions were incubated at
37 #Cwith stirring at 200 rpm. After 3 h of incubation, bacteriawere
washed with PBS (Lonza) by centrifugation at 3800 rpm for 10 min
and the pellets were resuspended in simulated intestinal fluid
(pancreatin 0.1% w/v, bovine bile salts 0.15% w/v) at a final pH
adjusted to 8.0. Then, suspensions were incubated at 37 #C for 3 h
with stirring at 200 rpm. Cell viability was assayed by plating
samples collected after incubation in simulated gastric fluid and
after incubation in simulated intestinal fluid. The percentage of
bacterial survival was calculated as follows:
CFUassay
CFUcontrol
$ 100
where CFUassay represents CFU after incubation in simulated gastric
or intestinal fluids and CFUcontrol the CFU after incubation in PBS as
a control. Separate experiments were performed three times.
Table 1
Strains tested.
Species Strains Origins
Probiotics
Bifidobacterium bifidum 02 new-born faeces
Bifidobacterium bifidum 20 new-born faeces
Bifidobacterium breve R0070 Lallemand
Bifidobacterium longum R0175 Lallemand
Bifidobacterium pseudocatenulatum 14 new-born faeces
Lactobacillus acidophilus R0240 Lallemand
Lactobacillus buchneri R1102 Lallemand
Lactobacillus farciminis CIP103136 Institut Pasteur Collection
Lactobacillus helveticus R0052 Lallemand
Lactobacillus plantarum R1012 Lallemand
Lactobacillus rhamnosus R1102 Lallemand
Lactococcus lactis R1058 Lallemand
Pediococcus acidilactici R1001 Lallemand
Streptococcus thermophilus R0083 Lallemand
Enteric pathogens
Escherichia coli serotype O157:H7 CIP 103571 Institut Pasteur Collection
Salmonella enterica ssp. enterica CIP 60.62T Institut Pasteur Collection
serotype typhimurium
Campylobacter jejuni CIP 70.2T Institut Pasteur Collection
Clostridium difficile CIP 104282 Institut Pasteur Collection
Enterococcus faecalis CIP 106996 Institut Pasteur Collection
Listeria monocytogenes CIP 82.110T Institut Pasteur Collection
Candida albicans UMIP 884.65 Institut Pasteur Collection
2.3.2. Growth inhibition of pathogenic strains
Growth inhibition of pathogenic strains by probiotics was eval-
uated using an agar spot test [23]. Briefly, 8 mL of each probiotic
suspension at 1 $108 CFU/mL was spotted onto the surface of MRS
agar plates and incubated anaerobically at 37 #C for 48 h. Pathogenic
strains were then inoculated in 5 mL of soft agar (containing 0.7%
agar) in an appropriate medium, described previously, at a final
concentration of 1 $ 107 CFU/mL, and poured onto MRS agar with
probiotic spots. The plates were incubated in conditions suitable for
each pathogen for 24e48 h. Growth inhibition was then measured.
Considering the diameter of inhibition in mm, significant inhibition
was defined for inhibition areas having a diameter of at least 50mm,
intermediate inhibitionwhen thediameterwasbetween20mmand
50 mm, and inability to inhibit the pathogen for diameters of less
than 20 mm. Separate experiments were performed three times.
2.4. Evaluation of glucooligosaccharides for use as carbon source
2.4.1. Probiotic growth on glucooligosaccharides
Glucooligosaccharide consumption by probioticswas evaluated in
microtitre plates. MRS broth was reconstituted without glucose
according to the composition previously described [24] and
completed by filter-sterilised (0.2 mm) glucooligosaccharide solution
orglucosesolutionaspositive control atafinal concentrationof10g/L.
Each well was inoculated with overnight cultures at a final concen-
tration of 1 $ 107 CFU/mL. Chemically induced anaerobic conditions
were obtainedwithascorbate at afinal concentrationof 1mg/mL. The
microtitre plates were sealed with a plastic film in sterile conditions.
Growth parameters were kinetically monitored using a POLARstar
Galaxy automated microplate reader (BMG Labtech, Offenburg,
Germany). Turbiditywas assayed at 640nmevery 15minduring 36 h
of incubation at 37 #C pHvaluesweremonitored at the beginning and
end of the cultures. The growth parameters were calculated by stan-
dard methods. Separate experiments were performed three times.
2.4.2. High performance liquid chromatography analyses
As the glucooligosaccharides tested were mixtures of different
degrees of polymerisation (DP), high performance liquid chroma-
tography analyses were performed to quantify the preferentially
consumed DP of each glucooligosaccharide when the probiotic
culture reached the stationary phase. Samples were prepared as
follows: supernatants from probiotic strain growth assays on glu-
cooligosaccharideswere collectedbycentrifugation (3600g/10min)
and filtered (0.2 mm) for residue removal. Standards were glucose,
fructose and saccharose. The solutions were then analysed by HPLC
(Ultimate 3000; Dionex, Sunnyvale, USA) on a C18 Synergi 4 mm
hydro-RP 80A column (Phenomenex, Torrance, USA). Elution was
performed with ultrapure water at a flow rate of 1 mL/min at 50 #C.
Glucooligosaccharide content was determined by refractive
index detection (RI-101; Shodex, Kawasaki, Japan). The results were
expressed as percentages of consumption of each DP of the glu-
cooligosaccharides, corresponding to the following ratio:
½CS&0"½CS&t
½CS&0
$ 100
where [CS]t represents the concentration of each DP at time t of
culture and [CS]0 the concentration measured at time 0. Peaks
related to media components were monitored and subtracted from
the area of the corresponding DP. Separate experiments were per-
formed three times.
2.4.3. Pathogen growth on glucooligosaccharides
The growth of pathogenic strains on oligosaccharide carbon
source was assayed in appropriate reconstituted broth without
glucose and completed with filter-sterilised (0.2 mm) glucooligo-
saccharide solution or glucose solution, as the positive control, at
a final concentration of 10 g/L. Five mL of each medium was inoc-
ulated with overnight cultures at a final concentration of
1$107 CFU/mL. Strains were cultivated at 37 #C for 48 h as follows:
(i) in reconstituted trypcase soy broth under aerobic conditions
with stirring for E. coli serotype O157:H7 CIP 103571, S. enterica
subsp. enterica serotype tiphymurium CIP 60.62T and E. faecalis CIP
106996, (ii) in reconstituted Schaedler broth under aerobic condi-
tions for L. monocytogenes CIP 82.110T or (iii) under anaerobic
conditions for C. difficile CIP 104282 and (iv) under microaerophilic
conditions for C. jejuni CIP 70.2T, (v) on Sabouraud under aerobic
conditions with stirring for C. albicans UMIP 884.65. Turbidity at
640 nm was determined at the end of the log phase. The growth
parameters were calculated by standard methods. Separate
experiments were performed three times.
3. Results
3.1. Investigation for probiotic properties
3.1.1. Resistance to simulated gastric and intestinal fluids
Probiotic survival rates are presented in Fig. 1. The bifidobacteria
had high survival rates in both simulated gastric and intestinal
conditions except for Bifidobacterium longum, which showed a loss
of viability >50% after treatment by intestinal fluid. Lactobacillus
helveticus and Lactobacillus plantarum were also strongly resistant
to the various conditions. Lactobacillus rhamnosus, L. lactis, P. acid-
ilactici and S. thermophilus were resistant to the artificial gastric
juice but were inhibited to a greater extent by simulated intestinal
fluid. P. acidilactici was the least sensitive among the latter strains,
while the two strains of Lactobacillus acidophilus, Lactobacillus
buchneri and S. thermophiluswheremuch less resistant. L. farciminis
had very poor resistance properties in both gastric and intestinal
conditions.
3.1.2. Growth inhibition of pathogenic strains
The inhibitory activity exerted by probiotics against pathogens
is presented in Table 2. Among the bifidobacteria, only Bifido-
bacterium breve and B. bifidum 02 presented a high inhibitory effect
against Gram positive bacteria, respectively C. difficile and E. fae-
calis, whereas B. bifidum 20 significantly inhibited E. coli serotype
O157:H7 as well as S. thermophilus. L. farciminis was the most
effective strain for inhibiting pathogen growth with strong effects
against the Gram negative and Gram positive bacteria: S. typhi, C.
jejuni and L. monocytogenes. L. heleveticus was also able to inhibit
growth of C. jejuni and C. difficile, and L. buchneri had a strong
activity against C. jejuni. Concerning the other genera, P. acidilactici
exerted strong inhibitory activities against C. jejuni and C. difficile
and S. thermophilus had antimicrobial effects against E. coli
O157:H7. The other strains exerted only intermediate inhibition
effects. None of the strains was able to significantly inhibit the
growth of C. albicans.
3.2. Evaluation of glucooligosaccharides for use as a carbon source
3.2.1. Probiotic growth on glucooligosaccharides
Kinetic analyses were used to monitor consumption of glucoo-
ligosaccharides by probiotics. The experimental conditions were
validated by checking with positive and negative control experi-
ments performed respectively with modified MRS broth com-
plemented with glucose or without any carbon source. Table 3
presents the growth parameters for all the strains tested in pres-
ence of the different carbohydrates.
Turbidity, generation time and pH values showed significant
growth on OA for all the six bifidobacteria strains and no significant
growth rates for lactobacilli. All the bifidobacteria were also able to
grow on OD whereas only three of the lactobacilli and L. lactis used
this carbohydrate. Microbial development on resistant rOD did not
reach significant levels in any strain.
3.2.2. High performance liquid chromatography analyses
Supernatants from cultures supporting a significant growth in
presence of OD and OA were collected at the stationary phase of
culture and subjected to HPLC analyses in order to determine the
degradation rate of each oligosaccharide DP during bacterial
growth. The results are listed in Table 4.
Concerning OD, all the strains tested consumed most of the DP3
and DP4 ('80%) except B. bifidum 02, L. helveticus and L. rhamnosus
for DP4. DP5 were strongly consumed by B. bifidum 01, B. breve,
B. longum and L. farciminiswhereas L. lactiswas the only strain able
to consume DP6 at a similar rate. DP7 and DP8 were poorly
hydrolysed in our conditions. Concerning OA, DP3 were consumed
by the six bifidobacteria at some intermediate rates (between 50%
and 65%). DP ' 3 were poorly metabolised.
These results suggest the potential use of OD and, to a lesser
degree, OA in synbiotic combination with the selected probiotic
strains. These carbohydrates were investigated to determine their
resistance to pathogenic strains.
3.2.3. Pathogen growth on glucooligosaccharides
OD and OA were subjected to assays with intestinal pathogenic
bacteria. Positive and negative controls were conducted in recon-
stituted media with glucose or no carbon source. Fig. 2 presents the
turbidity reached by each strain at the stationary phase of culture.
For all pathogenic microorganisms, growth on glucooligo-
saccharides did not exceed the negative control average value and
remained markedly below the glucose control. These data
demonstrate that the intestinal pathogens tested were unable to
metabolise OD and OA and suggest a potential use of glucooligo-
saccharides as safe prebiotics or, combined with probiotics, in
synbiotics.
Fig. 1. Survival rates of probiotic strains after 3 h of exposure to simulated gastric fluid (black bars) and after a consecutive 3 h of exposure to simulated intestinal fluid (white bars).
Results are given as the average value of three different experiments ( standard deviation.
Table 2
Pathogen growth inhibition by probiotics expressed in diameter of inhibition expressed in mm. ND means no significant results.
Probiotics Pathogenic strains
Gram negative bacteria Gram positive bacteria Yeast
E. coli serotype
O157:H7 CIP 103571
S. enterica ssp. enterica serotype
typhimurium CIP 60.62T
C. jejuni
CIP 70.2T
C. difficile
CIP 104282
E. faecalis
CIP 106996
L. monocytogenes
CIP 82.110T
C. albicans
UMIP 884.65
B. bifidum 02 27 ((4) 31 ((2) 46 ((4) 40 ((4) 70 ((8)a 25 ((2) ND
B. bifidum 20 53 ((4)a 38 ((5) 33 ((2) ND 22 ((3) 33 ((3) ND
B. breve R0070 29 ((2) 23 ((2) 35 ((1) 58 ((1)a 24 ((1) 26 ((3) 19 ((1)
B. longum R0175 27 ((3) 36 ((3) 37 ((3) 35 ((3) 25 ((4) 29 ((4) 17 ((2)
B. pseudocatenulatum 14 30 ((4) 35 ((3) 45 ((1) 36 ((1) 28 ((2) 35 ((4) ND
L. acidophilus R0240 35 ((3) 35 ((3) 40 ((2) 41 ((2) 21 ((3) 46 ((4) 16 ((2)
L. buchneri R1102 31 ((2) 33 ((4) 56 ((4)a 46 ((1) 19 ((2) 31 ((3) 17 ((1)
L. farciminis CIP 1031136 36 ((4) 58 ((7)a 50 ((1)a 39 ((1) 26 ((4) 53 ((6)a 16 ((1)
L. helveticus R0052 44 ((4) 22 ((2) 53 ((1)a 52 ((2)a 32 ((2) 22 ((2) 26 ((2)
L. plantarum R1012 34 ((4) 35 ((4) 17 ((1) 29 ((4) 31 ((3) 21 ((3) 21 ((1)
L. rhamnosus R0011 44 ((5) 22 ((4) 50 ((1) 41 ((2) 31 ((4) 38 ((3) 19 ((3)
L. lactis R0058 28 ((3) 25 ((2) 36 ((1) 35 ((1) ND 21 ((3) ND
P. acidilactici R1001 39 ((4) 38 ((4) 50 ((4)a 53 ((2)a 35 ((3) 28 ((4) 21 ((2)
S. thermophilus R0083 50 ((5)a 26 ((2) 32 ((3) 32 ((6) 23 ((3) 29 ((2) 15 ((2)
a Means inhibitions considered as significant (diameter > 50 mm).
4. Discussion
In this study, we first aimed to evaluate some probiotic char-
acteristics of a panel of lactic acid bacteria. To be considered as
probiotic, microorganisms had to meet some selection criteria.
Among all the in vitro parameters defined (human origin for human
use, survival in gastrointestinal conditions, pathogen inhibition,
adhesion to intestinal epithelial cells, etc.) we chose to test resis-
tance to acidic and bile salt conditions along the digestive tract and
antimicrobial activity as defined previously [25]. Exposure to
gastric and intestinal fluids along the digestive tract is the main
stress that could decrease the viability of ingested probiotics [26].
Optimum delivery of viable microorganisms to the distal gut is
critical for intestinal probiotic effects [27] and acid resistance is
required for food applications. Thus we investigated the probiotics’
resistance through a protocol simulating gastric and intestinal
conditions as already described [22]. Most of the strains were
resistant to gastric conditions but had more variable resistance
profiles to artificial intestinal fluid. This decrease in viability after
the transition to intestinal fluid from gastric fluid has been
described previously and may be due to the rapid pH shift from
acidic to basic conditions [28]. The observed variations of such
resistance could be explained by strain dependent responses as
reported previously [29] and provide us with a first-level relevant
selection criterion, highlighting the strongest resistance effects of
the bifidobacteria in the present study. Pathogen inhibition is also
a major probiotic selection criterion and this mechanism is
involved in the restoration of gut microbiota balance [30]. It thus
has significant positive effects in various physiological functions
and in the reduction of pathologies such as inflammatory bowel
disease or colorectal cancer [31e33]. Here, the antimicrobial effects
exerted by the lactic acid bacteria tested were strain-specific. Three
strains among the Gram positive and Gram negative intestinal
pathogens were inhibited significantly by three of the six bifido-
bacteria. Lactobacilli showed the most effective antimicrobial
properties overall, with a noteworthy effect of L. farciminis and
a lesser but significant effect of L. helveticus. P. acidilactici also
showed significant antimicrobial properties. C. albicans resistance
to antagonist activities exerted by probiotics has been described
previously [12] and explained by yeast resistance to acidic condi-
tions, oxidative stress or bacteriocins, which are among the main
mechanisms involved in probiotic antibacterial activities [34].
These variations could be used as a second screening criterion.
Some of the strains displaying interesting antimicrobial properties
were active against only one or a few pathogenic strains. A broader
antibacterial activity could be obtained by combining probiotics,
Table 3
Growth parameters of probiotic cultures on selected oligosaccharides or glucose as positive control after 48 h of incubation. Results are given as average values of three
samples ( standard deviation. ND means no significant results.
Tested strains Growth parameters
Dmax T
a Gb Dmax pH
c
Glucose OA OD Glucose OA OD Glucose OA OD
B. bifidum 02 1.37 ((0.20) 0.71 ((0.38) 0.77 ((0.03) 05h20 ((01h47) 10h40 ((00h24) 05h02 ((01h59) 1.7 ((0.2) 0.3 ((0.1) 1.2 ((0.4)
B. bifidum 20 1.28 ((0.08) 0.58 ((0.09) 0.72 ((0.10) 03h39 ((00h40) 08h07 ((01h35) 05h52 ((01h18) 1.6 ((0.3) 0.4 ((0.1) 1.6 ((0.1)
B. breve R0070 1.39 ((0.13) 0.67 ((0.04) 0.95 ((0.07) 03h14 ((00h28) 11h36 ((03h54) 06h24 ((01h33) 1.8 ((0.1) 1.1 ((0.2) 1.6 ((0.1)
B. longum R0175 1.31 ((0.04) 0.86 ((0.15) 0.71 ((0.12) 03h03 ((00h39) 08h38 ((01h58) 03h22 ((00h46) 1.7 ((0.4) 1.4 ((0.2) 1.9 ((0.1)
B. pseudocatenulatum 14 1.11 ((0.09) 0.57 ((0.24) 0.75 ((0.11) 06h08 ((01h03) 06h40 ((01h47) 04h52 ((01h31) 1.7 ((0.2) 0.3 ((0.1) 1.1 ((0.2)
L. acidophilus R0240 0.64 ((0.01) ND ND 03h16 ((01h00) ND ND 1.5 ((0.4) ND ND
L. buchneri R1102 1.09 ((0.13) ND ND 05h39 ((01h33) ND ND 1.7 ((0.2) ND ND
L. farciminis CIP 103136 1.20 ((0.04) ND 0.95 ((0.19) 02h03 ((00h36) ND 05h27 ((01h55) 1.7 ((0.2) ND 1.6 ((0.6)
L. helveticus R0052 1.28 ((0.27) ND 0.79 ((0.08) 04h18 ((00h27) ND 05h26 ((01h22) 1.7 ((0.3) ND 1.3 ((0.8)
L. plantarum R1012 1.31 ((0.03) ND ND 04h46 ((00h08) ND ND 1.8 ((0.2) ND ND
L. rhamnosus R0011 1.34 ((0.09) ND 0.67 ((0.22) 02h32 ((00h02) ND 06h41 ((00h46) 1.8 ((0.1) ND 1.2 ((0.5)
L. lactis R1058 0.55 ((0.07) ND 0.59 ((0.23) 01h39 ((00h04) ND 02h32 ((00h48) 1.6 ((0.2) ND 1.7 ((0.4)
P. acidilactici R1001 0.99 ((0.11) ND ND 02h03 ((00h36) ND ND 1.8 ((0.5) ND ND
S. thermophilus R0083 0.92 ((0.20) ND ND 01h59 ((00h41) ND ND 0.7 ((0.3) ND ND
a
Dmax T ¼ maximal variation of turbidity at 640 nm compared to the initial value.
b G ¼ generation time (h:min).
c
Dmax pH ¼ maximal variation of pH compared to the initial value.
Table 4
Percentage of consumption by probiotics of each degree of polymerisation (DP) of selected oligosaccharides after 48 h of incubation. Results are given as average values of three
samples ( standard deviation. ND means no significant results.
Tested strains Carbohydrates
OD OA
DP3 DP4 DP5 DP6 DP7 DP8 DP3 DP > 3
B. bifidum 02 97 ((2) 86 ((5) 71 ((10) 55 ((25) 30 ((4) 15 ((6) 49 ((11) 15 ((7)
B. bifidum 20 96 ((1) 38 ((6) 39 ((3) 21 ((4) 18 ((3) 18 ((1) 61 ((4) 21 ((7)
B. breve R0070 95 ((2) 94 ((1) 84 ((3) 35 ((25) 19 ((10) 12 ((8) 66 ((3) 22 ((1)
B. longum R0175 97 ((3) 96 ((3) 86 ((1) 48 ((4) 44 ((3) 2 ((1) 65 ((1) 40 ((3)
B. pseudocatenulatum 14 98 ((2) 78 ((9) 48 ((10) 39 ((11) 31 ((16) 23 ((1) 50 ((8) 9 ((7)
L. acidophilus R0240 ND ND ND ND ND ND ND ND
L. buchneri R1102 ND ND ND ND ND ND ND ND
L. farciminis CIP 103136 98 ((1) 83 ((14) 84 ((7) 62 ((23) 22 ((4) 20 ((7) ND ND
L. helveticus R0052 97 ((3) 39 ((25) 32 ((12) 29 ((15) 23 ((3) 13 ((8) ND ND
L. plantarum R1012 ND ND ND ND ND ND ND ND
L. rhamnosus R0011 75 ((11) 33 ((27) 26 ((16) 25 ((22) 19 ((13) 16 ((7) ND ND
L. lactis R1058 94 ((5) 85 ((2) 60 ((6) 81 ((7) 38 ((9) 14 ((9) ND ND
P. acidilactici R1001 ND ND ND ND ND ND ND ND
S. thermophilus R0083 ND ND ND ND ND ND ND ND
especially among the lactobacilli tested strains that were the most
effective against the different pathogens.
The second aim of this study was to select some probiotic strains
able to grow on glucooligosaccharides, which are potential prebi-
otic carbohydrates, in order to propose a rational selection of
original synbiotic combinations in vitro. Some works have previ-
ously demonstrated glucooligosaccharide fermentability charac-
teristics with an induction of bifidobacteria and lactobacilli
populations of human colonic microflora [35] or their potential
prebiotic effects on vaginal lactobacilli [12]. The microoganisms
tested did not use rOD. The absence of significant growth on rOD
may be due to the chemical structure of this carbohydrate including
an a-1,2 glycosidic bond at the non-reducing end or at branch point
[21], which is very uncommon. This glucooligosaccharide was
demonstrated to be more resistant than dextran with only a-1,6
glycosidic bonds in pH-controlled fermenters and was more
significantly hydrolysed in in vivo conditions [36]. This suggests
that the lack of growth on rOD could also be due to our experi-
mental conditions, which were characterised by batch conditions,
with no pH control and no renewal of nutrients in the culture
medium. This is very different from an intestinal ecosystem with
a great diversity of microorganisms, where more favourable
conditions could lead to the expression of some enzymes involved
in specific glycosidic bond hydrolyses. In consistency with probiotic
bacteria growth parameters, we confirmed some fermentability
characteristics here for two glucooligosaccharides, displaying some
potential synbiotic uses: OD and OA. OD was metabolised by
a larger number of lactic acid bacterial strains and promoted
bacterial growth more efficiently than OA. Bifidobacterium was
more effective than the other genus in metabolising glucooligo-
saccharides as a carbon source. Bifidobacteria possess a wide range
of genes involved in carbohydrate catabolism [37] and have been
described for their ability to grow on several short-chain oligo-
saccharides, such as fructooligosaccahrides and xylooligo-
saccahrides [38,39]. Among these short-chain carbohydrates,
bifidobacteria are able to metabolise OD in batch cultures [40,41]
and to hydrolyse OA [42]. OA can also support specific intestinal
bacterial growth [43]. Moreover, the absence of significant growth
of intestinal pathogens on OD and OA showed the specificity of the
metabolisation by probiotics and thus conferred potential prebiotic
characteristics on them. This finding is important as some potential
prebiotics have been demonstrated to induce the development of
pathogenic bacteria in animal models [44]. These properties need
to be confirmed in gut models in vitro or in assays in vivo in order to
assess the selective growth effects of the tested glucooligo-
saccharides on positive bacteria in the context of a diversified
microbial community.
OD were more effective than OA to promote development of
some lactic acid bacteria when generation time and turbidity at
stationary phase culture were considered. This suggests a faster
metabolisation of OD than OA by bifidobacteria.
Five of the six bifidobacteria that grew on OD and OA were
resistant to the artificial gastric and intestinal conditions but only
three of the four lactobacilli using OD were resistant. Some of these
glucooligosaccharide-fermenting strains were also able to inhibit
intestinal pathogenic bacteria, especially L. farciminis, which had
antimicrobial characteristics against one Gram positive and two
Gram negative pathogens. However, this tested strainwas the most
affected by the digestive tract conditions. Considering the good
probiotic characteristics displayed in vitroby L. farciminis CIP 103136
in this study and its anti-inflammatory and anti-nociceptive effects
[45,46], this strain should be assayed in formulations enhancing
protection against damage induced by gastrointestinal transit, such
as microencapsulation in gel beads [47] or ingestion with milk,
soymilk or dairy products which buffer the pH variation that can
occuralong thedigestive tract [48,49]. The same techniques couldbe
used to protect other interesting strains before an in vivo evaluation
of probiotic or synbiotic properties. HPLC analyses showed a pref-
erential consumption of shorter OD DP and only OA DP3 were
significantly consumed. Short DP preferential metabolisation could
be explained by a faster consumption of these polymers or could be
induced by batch conditions with a lack of some nutriments after
Fig. 2. Maximal variation of turbidity at 640 nm of pathogenic cultures on glucose as positive control (white bars), without carbohydrates as negative control (black bars) or selected
oligosaccharides, oligoalternan (hatched bars) and oligodextran (dotted bars) after 48 h of incubation. Results are given as the average value of three different experiments( standard
deviation. * Different from negative control with no carbohydrates, P < 0.05.
a certain period of bacterial growth. Extended time of analysis or
continuous conditions could help to check whether bacteria (lac-
tobacilli, Pediococcus and Streptococcus) are able tometabolise larger
DP or not, or if it is possible to improve bifidobacteria growth on OA.
It would be interesting to test these two glucooligosaccharides
enriched in preferentially consumed DP in an attempt to optimise
lactic acid bacteria growth. Bifidobacteriawere themost effective in
using glucooligosaccharides as a carbon source but displayed low
antimicrobial characteristics, whereas lactobacilli, P. acidilactici and
S. thermophilus significantly inhibited pathogenic strains but were
generally less resistant to digestive tract conditions andwere unable
to grow on glucooligosaccharides. These observations suggest the
use of associations of strains with complementary properties. Some
studies have already highlighted the interest of combinations of
different probiotic strains, especially bifidobacteria and lactobacilli,
to improve their intrinsic properties [50,51].
In conclusion, some of the strains tested displayed interesting
probiotic characteristics and two potential prebiotic glucooligo-
saccharides, OD and OA, were selected for their ability to support
growth of specific probiotic bacteria. These carbohydrates need to
be assayed in models in vivo to demonstrate their potential prebi-
otic properties before proceeding to clinical trial. Bifidobacteria
were the most resistant to the gastrointestinal conditions and the
most effective in metabolising glucooligosaccharides, and lactoba-
cilli displayed the strongest inhibitory effects on enteric pathogens.
A combination of a glucooligosaccharide-fermenting bacterium
with a non-fermenting one could also improve the glucooligo-
saccharides metabolisation for the latter and extend the antibac-
terial spectrum. Thus this study has identified some potential
synbiotics to be further evaluated for beneficial effects through
interaction with human cells in assays in vitro and to extend the
screening to in vivo models before potential use in human
applications.
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